Nuclear receptors reverse McGarry's vicious cycle to insulin resistance - PubMed (original) (raw)
Nuclear receptors reverse McGarry's vicious cycle to insulin resistance
David D Moore. Cell Metab. 2012.
Erratum in
- Cell Metab. 2012 Jun 6;15(6):925
Abstract
Several pathways and pathologies have been suggested as connections between obesity and diabetes, including inflammation of adipose and other tissues, toxic lipids, endoplasmic reticulum stress, and fatty liver. One specific proposal is that insulin resistance induces a vicious cycle in which hyperinsulinemia increases hepatic lipogenesis and exacerbates fatty liver, in turn further increasing insulin resistance. Here I suggest that reversing this cycle via suppression of the lipogenic transcription factor SREBP-1c is a common thread that connects the antidiabetic effects of a surprising number of nuclear hormone receptors, including CAR, LRH-1, TRβ, ERα, and FXR/SHP.
Copyright © 2012 Elsevier Inc. All rights reserved.
Figures
Figure 1. Proposed model for McGarry’s lipogenic vicious cycle, and its reversal
In the red, counterclockwise cycle, insulin resistance generates a self-reinforcing negative regulatory loop in which elevated insulin levels increase SREBP-1c expression and steatosis. This further decreases insulin sensitivity and increases in serum insulin levels to continue the negative cycle. Several NRs, including ERα CAR, LRH-1 TRβ and FXR/SHP act to decrease SREBP-1c expression, lowering steatosis and setting up a positive, anti-lipogenic cycle to improved insulin sensitivity.
References
- Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am. 2007;91:1125–1149. ix. - PubMed
- Amengual J, Ribot J, Bonet ML, Palou A. Retinoic acid treatment enhances lipid oxidation and inhibits lipid biosynthesis capacities in the liver of mice. Cell Physiol Biochem. 2010;25:657–666. - PubMed
- Angelin B, Rudling M. Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol. 2010;21:499–506. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 DK046546/DK/NIDDK NIH HHS/United States
- DK-079638/DK/NIDDK NIH HHS/United States
- P30 DK079638/DK/NIDDK NIH HHS/United States
- R01 DK083572/DK/NIDDK NIH HHS/United States
- R01 DK085372/DK/NIDDK NIH HHS/United States
- R01 DK068804/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical